JP2004534533A5 - - Google Patents

Download PDF

Info

Publication number
JP2004534533A5
JP2004534533A5 JP2003500199A JP2003500199A JP2004534533A5 JP 2004534533 A5 JP2004534533 A5 JP 2004534533A5 JP 2003500199 A JP2003500199 A JP 2003500199A JP 2003500199 A JP2003500199 A JP 2003500199A JP 2004534533 A5 JP2004534533 A5 JP 2004534533A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
peptide
condition
ntp peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003500199A
Other languages
English (en)
Japanese (ja)
Other versions
JP4584573B2 (ja
JP2004534533A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2002/000759 external-priority patent/WO2002097030A2/en
Publication of JP2004534533A publication Critical patent/JP2004534533A/ja
Publication of JP2004534533A5 publication Critical patent/JP2004534533A5/ja
Application granted granted Critical
Publication of JP4584573B2 publication Critical patent/JP4584573B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003500199A 2001-05-25 2002-05-24 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド Expired - Fee Related JP4584573B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29315601P 2001-05-25 2001-05-25
PCT/CA2002/000759 WO2002097030A2 (en) 2001-05-25 2002-05-24 Peptides derived from neural thread proteins and their medical use

Publications (3)

Publication Number Publication Date
JP2004534533A JP2004534533A (ja) 2004-11-18
JP2004534533A5 true JP2004534533A5 (cg-RX-API-DMAC7.html) 2005-12-22
JP4584573B2 JP4584573B2 (ja) 2010-11-24

Family

ID=23127882

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003500199A Expired - Fee Related JP4584573B2 (ja) 2001-05-25 2002-05-24 細胞の除去または破壊を必要とする腫瘍および他の状態の処置に有効なペプチド

Country Status (17)

Country Link
US (1) US6924266B2 (cg-RX-API-DMAC7.html)
EP (1) EP1390403B1 (cg-RX-API-DMAC7.html)
JP (1) JP4584573B2 (cg-RX-API-DMAC7.html)
KR (1) KR100945383B1 (cg-RX-API-DMAC7.html)
CN (1) CN1582301A (cg-RX-API-DMAC7.html)
AT (1) ATE350396T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002256587B2 (cg-RX-API-DMAC7.html)
BR (1) BR0209990A (cg-RX-API-DMAC7.html)
CA (1) CA2448348C (cg-RX-API-DMAC7.html)
CY (1) CY1111120T1 (cg-RX-API-DMAC7.html)
DE (1) DE60217326T2 (cg-RX-API-DMAC7.html)
DK (1) DK1390403T3 (cg-RX-API-DMAC7.html)
ES (1) ES2278916T3 (cg-RX-API-DMAC7.html)
NO (1) NO334189B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ529911A (cg-RX-API-DMAC7.html)
PT (1) PT1390403E (cg-RX-API-DMAC7.html)
WO (1) WO2002097030A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60222745T2 (de) * 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
EP1847550A3 (en) * 2001-07-19 2008-01-09 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DE60217507T2 (de) * 2001-07-19 2007-11-15 Nymox Corp., Saint-Laurent Peptide für die behandlung von tumoren und anderen zuständen, die das entfernen oder zerstören von zellen erfordern
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CA2555306A1 (en) * 2004-02-06 2005-08-18 Nymox Corporation Humanized antibody
EP1732594A4 (en) * 2004-03-18 2007-10-17 St Lukes Hospital METHOD FOR THE ADMINISTRATION OF AGENTS WITH DELAYED RELEASE
EA200801942A1 (ru) * 2006-03-10 2009-02-27 Наймокс Корпорейшн Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон
CN101215323B (zh) * 2007-12-28 2011-11-30 首都医科大学宣武医院 人ad7c-ntp抗原决定簇多肽、抗体及其在诊断试剂盒上的应用
US20160361380A1 (en) 2015-06-12 2016-12-15 Nymox Corporation Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer
CN111579799A (zh) * 2020-06-23 2020-08-25 江苏省荣军医院 一种检测尿液中阿尔茨海默病相关神经丝蛋白的荧光免疫层析试纸的制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0378924B1 (en) * 1988-12-21 1996-11-13 The General Hospital Corporation Detection of neurological disease or dysfunction
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
AU749348B2 (en) * 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
AU9655698A (en) * 1997-10-10 1999-05-03 Astra Aktiebolag Synthetic genes with immunomodulatory effects
AU765110B2 (en) * 1998-06-26 2003-09-11 Georgetown University Medical Center Compositions and methods for inducing cell death
AU2185199A (en) * 1998-09-30 2000-04-17 Yoko Aida Apoptosis inducers
EP1135494A2 (en) * 1998-12-11 2001-09-26 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
DE60003632T2 (de) * 1999-01-11 2004-04-15 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
JP2002539842A (ja) 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド 45個のヒト分泌タンパク質
EP1171462A2 (en) * 1999-03-26 2002-01-16 Human Genome Sciences, Inc. 49 human secreted proteins
US7259232B1 (en) 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
DE60222745T2 (de) 2001-03-08 2008-07-10 Nymox Pharmaceutical Corp., St. Laurent Verwendung von neurofilamentproteinen zur behandlung von tumoren
JP2004529179A (ja) 2001-05-16 2004-09-24 ナイモックス コーポレーション 神経線維タンパク質のセグメントを使用する細胞死の予防法

Similar Documents

Publication Publication Date Title
JP2005507647A5 (cg-RX-API-DMAC7.html)
JP2005506061A5 (cg-RX-API-DMAC7.html)
JP2005521383A5 (cg-RX-API-DMAC7.html)
JP2004529908A5 (cg-RX-API-DMAC7.html)
JP2019196365A5 (cg-RX-API-DMAC7.html)
ES2255248T3 (es) Derivados de antigenos asociados a tumor de la familia mage, y secuencias de acidos nucleicos que los codifican, usados para la preparacion de proteinas de fusion y de composiciones para vacunas.
EA010435B1 (ru) Связывающиеся с tall-1 молекулы и их применение
JP2003531632A (ja) グルカゴンアンタゴニスト
CA2438143A1 (en) Modified proteins, designer toxins, and methods of making thereof
JP2007523633A5 (cg-RX-API-DMAC7.html)
JPH06502771A (ja) 筋細胞内での発現のためのウイルス性組換え型ベクター
KR20090045940A (ko) 세포자멸사의 억제를 위한 약학 조성물, 및 이를 전달하는 방법
WO2008085828A2 (en) Peptide modulators of angiogenesis and use thereof
JP2003505075A5 (cg-RX-API-DMAC7.html)
JP2021515572A5 (cg-RX-API-DMAC7.html)
JP2003530870A (ja) Apo−AI/AIIペプチド誘導体
CN113194978A (zh) 具有间充质干细胞的动员活性的肽
JP2024513559A5 (cg-RX-API-DMAC7.html)
BRPI0708737A2 (pt) mÉtodo de prevenÇço ou reduÇço do risco ou incidÊncia de cÂncer utilizando-se peptÍdeos baseados na proteÍna na cadeia neural
CN1504240A (zh) 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途
CA2378925A1 (en) Matrix-targeted fusion polypeptides for tissue regeneration and wound healing
CN111690071A (zh) 一种具有靶向穿膜性的抗肿瘤多肽
CN1182874C (zh) 糖尿病性局部缺血疾病的基因治疗制剂
CN119019494A (zh) 一种治疗心梗的脐带间充质干细胞及其制备方法和应用
JP7457413B2 (ja) 代謝障害に対する新規なfgf19タンパク質類似物質及びその使用